المؤلفون: Georges-Philippe Pageaux (330415), Clovis Lusivika Nzinga (12011451), Nathalie Ganne (3766546), Didier Samuel (374860), Céline Dorival (12011454), Fabien Zoulim (38093), Carole Cagnot (837401), Thomas Decaens (6291578), Dominique Thabut (38091), Tarik Asselah (717526), Philippe Mathurin (177542), François Habersetzer (424769), Jean-Pierre Bronowicki (126173), Dominique Guyader (3390698), Isabelle Rosa (12011457), Vincent Leroy (554796), Olivier Chazouilleres (3207366), Victor de Ledinghen (38098), Marc Bourliere (38094), Xavier Causse (12011460), Paul Cales (4110967), Sophie Metivier (12011463), Véronique Loustaud-Ratti (359961), Ghassan Riachi (12011466), Laurent Alric (336914), Moana Gelu-Simeon (5431361), Anne Minello (12011469), Jérôme Gournay (4261519), Claire Geist (12011472), Albert Tran (173885), Armand Abergel (4966900), Isabelle Portal (12011475), Louis d’Alteroche (12011478), François Raffi (4923), Hélène Fontaine (254668), Fabrice Carrat (28741), Stanislas Pol (254669)

مصطلحات موضوعية: Medicine, Biotechnology, Immunology, Cancer, Science Policy, Infectious Diseases, Virology, Computational Biology, Space Science, Chemical Sciences not elsewhere classified, Hepatitis C virus, Decompensated cirrhosis, Direst-acting antiviral agents, Survival, Hepatocellular carcinoma, Sustained virological response

Relation: https://figshare.com/articles/journal_contribution/Additional_file_1_of_Clinical_outcomes_after_treatment_with_direct_antiviral_agents_beyond_the_virological_response_in_patients_with_previous_HCV-related_decompensated_cirrhosis/19084110

الاتاحة: https://doi.org/10.6084/m9.figshare.19084110.v1